Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia

被引：86
作者：
Park, Sang Hyuk
Chi, Hyun-Sook [1 ]
Min, Sook-Kyung
Park, Borae G.
Jang, Seongsoo
Park, Chan-Jeoung
机构：
[1] Univ Ulsan, Dept Lab Med, Coll Med, Seoul 138736, South Korea
来源：
LEUKEMIA RESEARCH | 2011年 / 35卷 / 10期
关键词：
AML; Core binding factor; c-KIT; Mutation; Prognosis; COOPERATIVE-STUDY-GROUP; CBF-AML; T(8/21); FLT3; RAS; EXPRESSION; FREQUENT; RECEPTOR; KINASE; GENES;
D O I：
10.1016/j.leukres.2011.06.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
This study sought to define the prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia (CBF AML) patients. A total of 116 patients diagnosed as CBF AML in Asan Medical Center from January 1999 to May 2010 were enrolled in this study. We applied melting curve analyses and direct sequencing methods to confirm c-KIT mutations in exon 17 (mutKIT17) and exon 8 (mutKIT8). Of the total 116 patients, mutKIT17 were found in 36 (31%) and mutKIT8 were found in 7 (6%). In patients with t(8;21), prognosis was significantly poorer in those with mutKIT17 compared to those without the mutation. This difference was limited to adults. In patients with inv(16), there was no prognostic impact of c-KIT mutations. Therefore, an analysis of mutKIT17 in adult CBF AML patients with t(8; 21) is recommended as a means to predict prognosis. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1376 / 1383
页数：8
相关论文
共 24 条
[1]   Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) [J].
Boissel, N. ;
Leroy, H. ;
Brethon, B. ;
Philippe, N. ;
de Botton, S. ;
Auvrignon, A. ;
Raffoux, E. ;
Leblanc, T. ;
Thomas, X. ;
Hermine, O. ;
Quesnel, B. ;
Baruchel, A. ;
Leverger, G. ;
Dombret, H. ;
Preudhomme, C. .
LEUKEMIA, 2006, 20 (06) :965-970
[2]   Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study [J].
Cairoli, R ;
Beghini, A ;
Grillo, G ;
Nadali, G ;
Elice, F ;
Ripamonti, CB ;
Colapietro, P ;
Nichelatti, M ;
Pezzetti, L ;
Lunghi, M ;
Cuneo, A ;
Viola, A ;
Ferrara, F ;
Lazzarino, M ;
Rodeghiero, F ;
Pizzolo, G ;
Larizza, L ;
Morra, E .
BLOOD, 2006, 107 (09) :3463-3468
[3]   Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias [J].
Care, RS ;
Valk, PJM ;
Goodeve, AC ;
Abu-Duhier, FM ;
Geertsma-Kleinekoort, WMC ;
Wilson, GA ;
Gari, MA ;
Peake, IR ;
Löwenberg, B ;
Reilly, JT .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (05) :775-777
[4]   A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial [J].
Chevallier, Patrice ;
Hunault-Berger, Mathilde ;
Larosa, Fabrice ;
Dauriac, Charles ;
Garand, Richard ;
Harousseau, Jean-Luc .
LEUKEMIA RESEARCH, 2009, 33 (08) :1124-1126
[5]   Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia [J].
De, Jitakshi ;
Zanjani, Reza ;
Hibbard, Michele ;
Davis, Bruce H. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 128 (04) :550-557
[6]   Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? [J].
Dombret, Herve ;
Preudhomme, Claude ;
Boissel, Nicolas .
CURRENT OPINION IN HEMATOLOGY, 2009, 16 (02) :92-97
[7]   Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia [J].
Goemans, BF ;
Zwaan, CM ;
Miller, M ;
Zimmermann, M ;
Harlow, A ;
Meshinchi, S ;
Loonen, AH ;
Hählen, K ;
Reinhardt, D ;
Creutzig, U ;
Kaspers, GJL ;
Heinrich, MC .
LEUKEMIA, 2005, 19 (09) :1536-1542
[8]   The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial [J].
Grimwade, D ;
Walker, H ;
Harrison, G ;
Oliver, F ;
Chatters, S ;
Harrison, CJ ;
Wheatley, K ;
Burnett, AK ;
Goldstone, AH .
BLOOD, 2001, 98 (05) :1312-1320
[9]  
Hart SM, 2002, HAEMATOLOGICA, V87, P1307
[10]   AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2 [J].
Jiao, B. ;
Wu, C-F ;
Liang, Y. ;
Chen, H-M ;
Xiong, S-M ;
Chen, B. ;
Shi, J-Y ;
Wang, Y-Y ;
Wang, J-H ;
Chen, Y. ;
Li, J-M ;
Gu, L-J ;
Tang, J-Y ;
Shen, Z-X ;
Gu, B-W ;
Zhao, W-L ;
Chen, Z. ;
Chen, S-J .
LEUKEMIA, 2009, 23 (09) :1598-1604
123